Weekly ReportDec 8–14, 2025
Sepsis, week 50 edition
We read 21 papers and selected 3.
Summary
This week’s sepsis literature emphasized precision immunotherapy, mechanistically targeted host-response modulation, and increasingly dynamic risk stratification. The ImmunoSep randomized trial showed that immune-phenotype-guided anakinra or interferon-γ improved early organ dysfunction, although mortality was unchanged, while mechanistic studies identified endothelial ferroptosis, TGR5 signaling, mitochondrial DNA–TLR9 activation, and pyroptosis pathways as therapeutic targets. Clinical practice signals included possible preference for esmolol over landiolol, shorter or biomarker-guided neonatal antibiotic courses, dynamic ICG-guided antimicrobial dosing, and earlier ICU transfer. Prognostic research also advanced through machine-learning models, glycemic-variability monitoring, and reproducible EHR case-identification workflows.
Selected Articles
1. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
In the multicountry, double-blind ImmunoSep randomized clinical trial, immune phenotype-guided treatment with anakinra for macrophage activation-like syndrome or interferon-γ for sepsis-induced immunoparalysis increased the proportion of patients achieving a clinically meaningful SOFA reduction by day 9. The benefit was observed despite no significant improvement in 28-day mortality, and treatment-specific safety signals included anemia with anakinra and hemorrhage with interferon-γ.
Impact: This is the week’s strongest clinical trial because it provides rigorous multicountry evidence that immune endotyping can identify patients who benefit from targeted immunotherapy for organ dysfunction, while clearly defining the limitation that mortality benefit remains unproven.
Clinical Implications: Early ferritin and monocyte HLA-DR testing could support phenotype-based trial protocols or specialized sepsis pathways, but routine adoption should await mortality-powered studies and careful monitoring for anemia, bleeding, and other serious adverse events.
Key Findings
- Among 276 randomized patients, a day-9 SOFA response occurred in 35.1% with precision immunotherapy versus 17.9% with placebo.
- The difference in 28-day mortality was not statistically significant.
- Anemia increased with anakinra and hemorrhage increased with interferon-γ.
2. Endothelial mechanosensitive transcription factor BHLHE40 induced by Piezo1 suppresses endothelial ferroptosis and inflammation via SLC7A11.
This mechanistic study identified a Piezo1–calcium/calcineurin–NFAT2/HDAC1–BHLHE40–SLC7A11 pathway that links mechanical sensing to endothelial protection. BHLHE40 increased SLC7A11 expression, reduced oxidative and lipid-peroxidation injury, and suppressed ferroptosis. Endothelial-specific BHLHE40 overexpression reduced lung vascular leakage, neutrophil infiltration, and inflammatory cytokines in an LPS-induced injury model.
Impact: The paper reveals a previously underappreciated link between endothelial mechanotransduction and ferroptosis, offering a coherent molecular explanation for vascular barrier preservation in sepsis and several potential therapeutic entry points.
Clinical Implications: The pathway is not yet clinically actionable, but it supports development of endothelial-injury and ferroptosis biomarkers and testing of Piezo1, BHLHE40, or SLC7A11 modulation in clinically relevant polymicrobial sepsis models.
Key Findings
- Shear stress activated Piezo1 and induced BHLHE40 through calcium/calcineurin-dependent NFAT2–HDAC1 signaling.
- BHLHE40 directly increased SLC7A11 and protected endothelial cells from ferroptosis.
- Endothelial BHLHE40 overexpression reduced LPS-induced lung vascular leakage and inflammation in mice.
3. Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis.
A network meta-analysis of 10 randomized trials involving 1,035 adults found that esmolol reduced 28-day mortality and heart rate compared with standard care. Landiolol was associated with greater norepinephrine requirements than standard care and higher 28-day mortality than esmolol, although certainty for landiolol comparisons was low. The findings suggest that short-acting beta-blockers should not be treated as a class-equivalent intervention in septic shock.
Impact: This synthesis could influence bedside hemodynamic practice by distinguishing the apparent effects of two commonly discussed beta-blockers and by identifying a potential survival signal for esmolol.
Clinical Implications: Esmolol may be considered for carefully selected septic patients requiring heart-rate control, with continuous blood-pressure and vasopressor monitoring. The low certainty of landiolol comparisons and limited direct head-to-head evidence preclude definitive class-wide recommendations.
Key Findings
- Esmolol reduced 28-day mortality versus standard care with a pooled RR of 0.69.
- Esmolol reduced 24-hour heart rate by approximately 17 beats per minute versus standard care.
- Landiolol increased norepinephrine requirements and was associated with higher mortality than esmolol, with low certainty.